- About Us
- Who We Serve
- Our Tissues & Products
- Contact Us
MTF Biologics entered the breast reconstruction field because of surgeons like you. We had already established a reputation as an allograft innovator. Extending it into the Plastic Surgery arena, we listened—learning what common acellular dermal matrix (ADM) challenges you were dealing with. Since then, we’ve helped to develop breast reconstruction ADMs, nose reshaping grafts, soft tissue filling solutions and more—all designed to generate better surgical experiences and patient outcomes.
The Plastic Surgery Foundation (PSF) and MTF Biologics have joined forces to provide annual research grants to investigators studying allograft tissue transplantation in plastic and reconstructive surgery. Since 2013, the organizations have provided support for research projects focused on biologic reconstruction with a strong clinical translation component that use dermal, adipose, placental or other allograft transplant technologies. Learn more.
Grant applications for the 2018 Cycle are being accepted through December 3, 2018.
MTF Biologics breast reconstruction ADMs are the product of a deeper cut in the dermal tissue—procured from a cut below the dense collagen structure in the papillary dermis—which results in better handling and faster cell incorporation for enhanced healing.
Created exclusively for breast reconstruction in partnership with plastic surgeons nationwide, it’s the ADM you asked for:
Renuva is an off-the-shelf allograft adipose matrix engineered to treat small-volume aesthetic irregularities, the kind that detract from smooth contours and flawless skin, without the need for liposuction.
Renuva has numerous applications:
Science drives everything we do, from our research and development to our processing methods. And we prioritize clinically-based evidence. Explore our wide range of peer-reviewed, published studies outlining the safety of our tissue and excellent patient outcomes.